Investor Relations

DanCann Pharma A/S was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas.

DanCann Pharma was established due to the poor access for cannabinoid-based drugs and pharmaceuticals shortly after the establishment of the new Pilot Programme with medical cannabis in Denmark.

DanCann Pharma is licensed for handling of euphoriant substances, and during the summer 2018, the Company was licensed as one of the first companies in Denmark to handle and cultivate cannabis for medical use.

DanCann Pharma makes and distributes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis.

Share Information

The company is listed on Spotlight Stock Market and is traded with the ticker name DANCAN (ISIN code DK0061410487. DANCAN TO 1, ISIN code DK0061410560).

Initial Public Offering (2020)

DanCann Pharma A/S was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas.

DanCann Pharma is a Danish public limited company incorporated in Denmark and operating under Danish law.
The Issuer was founded on 20 March 2018 by CEO Jeppe Krog Rasmussen.

Description of DanCann Pharma as of 30 September 2020 see Prospectus below. More information about DanCann Pharma is available under Presentations or in the IPO Teasers. Subscriptions can be made through any of the following platforms:

Corporate Governance

DanCann Pharma A/S is a Danish public limited company governed by Danish legislation, mainly the Danish Companies Act and the Danish Annual Accounts Act.

Following the listing of the Company’s shares on Spotlight Stock Market, the Company will apply and adhere to Spotlight Stock Markets’ rules and regulations.

DanCann Pharma's law firm is Andersen Partners.
DanCann Pharma’s auditor is BDO, Denmark.

Financial Calendar

Year End Report
25. FEBRUARY 2022
Annual Report 2021
12. APRIL 2022
Annual General Meeting (AGM) 2022
27. APRIL 2022
Q1-2022 Report
18. MAY 2022
Q2-2022 Report
25. AUGUST 2022
Q3-2022 Report
4. NOVEMBER 2022

IR Contact

For additional information about DanCann Pharma A/S please contact:

Board of Directors